A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Recruiting
Phase 2
Phase 3
Interventional Study
Macular Degeneration
Age-Related Macular Degeneration
Choroidal Neovascularization
Wet Macular Degeneration
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 50 and older
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 960 (estimated)
- Sponsor
- EyeBiotech Ltd. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).
Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD.
The goal of this trial is to learn if tiespectus works as well as aflibercept to tre…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
The main inclusion criteria include but are not limited to the following:
* Has treatment naive choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) including subfoveal, juxtafoveal and extrafoveal lesions or retinal angiomatous proliferations (RAP) and polypoidal …
Contacts